Author contributions
Guillermo Hernández Silva: Studied the conception and designed the study, also reviewed the manuscript.
Ricardo Giovanni Puerto Chaparro: Studied the conception and designed the study, also reviewed the manuscript.
Javier Álvaro Martínez Melo: Studied the conception and designed the study, also reviewed the manuscript.
Cristian Orlando Porras Bueno: Wrote, reviewed the manuscript and also was involved in acquisition of data and analysis of data.
Javier Eduardo Martínez Rodríguez: Wrote, reviewed the manuscript and also was involved in acquisition of data and analysis of data.
Sharon Julieth González Trillos: Wrote, reviewed the manuscript and also was involved in acquisition of data and analysis of data.
References
1. Stolp J, Zaitsu M, Wood KJ. Immune Tolerance and Rejection in Organ Transplantation. Methods Mol Biol. 2019; 1899:159-180.
2. Noble J, Terrec F, Malvezzi P, Rostaing L. Adverse effects of immunosuppression after liver transplantation. Best Pract Res Clin Gastroenterol. 2021;54-55:101762. doi: 10.1016/j.bpg.2021.101762
3. Farouk SS, Rein JL. The Many Faces of Calcineurin Inhibitor Toxicity-What the FK?. Adv Chronic Kidney Dis. 2020;27(1):56-66. doi: 10.1053/j.ackd.2019.08.006
4. Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev. 2010;(1):CD007893. Published 2010 Jan 20. doi: 10.1002/14651858.CD007893.pub2
5. Nakata Y, Yoshibayashi M, Yonemura T, et al. Tacrolimus and myocardial hypertrophy. Transplantation. 2000;69(9):1960-1962. doi:10.1097/00007890-200005150-00039
6. Bowman LJ, Brennan DC, Delos-Santos R, Larue SJ, Anwar S, Klein CL. Tacrolimus-induced cardiomyopathy in an adult renal transplant recipient. Pharmacotherapy. 2015;35(12):1109-1116. doi:10.1002/phar.1666
7. Dehghani SM, Haghighat M, Imanieh MH, et al. Tacrolimus related hypertrophic cardiomyopathy in liver transplant recipients. Arch Iran Med. 2010;13(2):116-119.
8. Liu T, Gao Y, Gao YL, et al. Tacrolimus-related hypertrophic cardiomyopathy in an adult cardiac transplant patient. Chin Med J (Engl). 2012;125(7):1352-1354.
9. Atkison P, Joubert G, Barron A, et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet. 1995;345(8954):894-896. doi:10.1016/s0140-6736(95)90011-x
10. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies: An American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113(14):1807–16.
11. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: A position statement from the european society of cardiology working group on myocardial and pericardial diseases. Eur Heart J. 2008;29(2):270–6.
12. Atkison P, Joubert G, Barron A, et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet. 1995;345(8954):894-896. doi:10.1016/s0140-6736(95)90011-x
13. Noda K, Ukichi T, Furuya K, et al. Tacrolimus-induced hypertrophic cardiomyopathy in a patient with dermatomyositis. Rheumatology (Oxford). 2017;56(11):2037-2038. doi:10.1093/rheumatology/kex310
14. Bowman LJ, Brennan DC, Delos-Santos R, LaRue SJ, Anwar S, Klein CL. Tacrolimus-Induced Cardiomyopathy in an Adult Renal Transplant Recipient. Pharmacotherapy. 2015;35(12):1109-1116. doi:10.1002/phar.1666
15. Turska-Kmieć A, Jankowska I, Pawłowska J, et al. Reversal of tacrolimus-related hypertrophic cardiomyopathy after conversion to rapamycin in a pediatric liver transplant recipient. Pediatr Transplant. 2007;11(3):319-323. doi:10.1111/j.1399-3046.2006.00633.x
16. Méndez-Abad P, Zafra-Rodríguez P. Miocardiopatía hipertrófica en un recién nacido pretérmino con madre trasplantada renal [Hypertrophic cardiomyopathy in preterm newborn with kidney transplanted mother]. Arch Argent Pediatr. 2018;116(6):e749-e752. doi:10.5546/aap.2018.e749
17. Jarzembowski TM, John E, Panaro F, et al. Reversal of tacrolimus-related hypertrophic obstructive cardiomyopathy 5 years after kidney transplant in a 6-year-old recipient. Pediatr Transplant. 2005;9(1):117-121. doi:10.1111/j.1399-3046.2005.00260.x
18. Chang RK, McDiarmid SV, Alejos JC, Drant SE, Klitzner TS. Echocardiographic findings of hypertrophic cardiomyopathy in children after orthotopic liver transplantation. Pediatr Transplant. 2001;5(3):187-191. doi:10.1034/j.1399-3046.2001.00052.x
19. Kakhi S, Phanish MK, Anderson L. Dilated Cardiomyopathy in an Adult Renal Transplant Recipient: Recovery Upon Tacrolimus to Sirolimus Switch: A Case Report. Transplant Proc. 2020;52(9):2758-2761. doi:10.1016/j.transproceed.2020.06.011
20. McLeod J, Wu S, Grazette L, Sarcon A. Tacrolimus-Associated Dilated Cardiomyopathy in Adult Patient After Orthotopic Liver Transplant. J Investig Med High Impact Case Rep. 2017;5(2):2324709617706087. Published 2017 Apr 27. doi:10.1177/2324709617706087
21. Kakhi S, Phanish MK, Anderson L. Dilated Cardiomyopathy in an Adult Renal Transplant Recipient: Recovery Upon Tacrolimus to Sirolimus Switch: A Case Report. Transplant Proc. 2020;52(9):2758-2761. doi:10.1016/j.transproceed.2020.06.011
22 . Pappas PA, Weppler D, Pinna AD, et al. Sirolimus in pediatric gastrointestinal transplantation: the use of sirolimus for pediatric transplant patients with tacrolimus-related cardiomyopathy. Pediatr Transplant. 2000;4(1):45-49. doi:10.1034/j.1399-3046.2000.00083.x